FcRn binding properties of an abnormal truncated analbuminemic albumin variant

Clinical Biochemistry

Volumn 43, Issue 4-5, 2010, Pages 367-372

  Andersen, Jan Terje ^a   Daba, Muluneh Bekele ^a   Sandlie, Inger ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

Analbuminemia; Biodistribution; Clinical albumin variants; Enzyme linked immunosorbent assay; FcRn; Half life; IgG; Surface plasmon resonance

Indexed keywords

FC RECEPTOR; GLUTATHIONE TRANSFERASE; HUMAN SERUM ALBUMIN; IMMUNOGLOBULIN G; MUTANT PROTEIN;

ALBUMIN BLOOD LEVEL; ANALBUMINEMIA; ARTICLE; BINDING AFFINITY; BINDING KINETICS; BIOSENSOR; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; EMBRYO; ENZYME LINKED IMMUNOSORBENT ASSAY; HALF LIFE TIME; HUMAN; HUMAN CELL; MOLECULAR CLONING; MOLECULAR WEIGHT; PH; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN VARIANT; SURFACE PLASMON RESONANCE; WILD TYPE;

AMINO ACID SEQUENCE; CELL LINE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOGLOBULIN G; MOLECULAR SEQUENCE DATA; MUTANT PROTEINS; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; RECEPTORS, FC; RECOMBINANT FUSION PROTEINS; SERUM ALBUMIN;

EID: 76749138019     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.12.001     Document Type: Article

References (43)

1. Peters T.J. All About Albumin: Biochemistry, Genetics, and Medical Applications (1996), Academic Press
2. Chuang V.T., Kragh-Hansen U., and Otagiri M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm. Res. 19 (2002) 569-607
3. Kragh-Hansen U., Chuang V.T., and Otagiri M. Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol. Pharm. Bull. 25 (2002) 695-704
4. Chaudhury C., Mehnaz S., Robinson J.M., et al. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J. Exp. Med. 197 (2003) 315-322
5. Burmeister W.P., Gastinel L.N., Simister N.E., Blum M.L., and Bjorkman P.J. Crystal structure at 2.2 A resolution of the MHC-related neonatal Fc receptor. Nature 372 (1994) 336-343
6. West Jr. A.P., and Bjorkman P.J. Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor. Biochemistry 39 (2000) 9698-9708
7. Anderson C.L., Chaudhury C., Kim J., Bronson C.L., Wani M.A., and Mohanty S. Perspective-FcRn transports albumin: relevance to immunology and medicine. Trends Immunol. 27 (2006) 343-348
8. Qiao S.W., Kobayashi K., Johansen F.E., et al. Dependence of antibody-mediated presentation of antigen on FcRn. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 9337-9342
9. Roopenian D.C., and Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7 (2007) 715-725
10. Vidarsson G., Stemerding A.M., Stapleton N.M., et al. FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis. Blood 108 (2006) 3573-3579
11. Andersen J.T., Dee Qian J., and Sandlie I. The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH-dependent binding to albumin. Eur. J. Immunol. 36 (2006) 3044-3051
12. Montoyo H.P., Vaccaro C., Hafner M., Ober R.J., Mueller W., and Ward E.S. Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice. Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 2788-2793
13. Akilesh S., Christianson G.J., Roopenian D.C., and Shaw A.S. Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism. J. Immunol. 179 (2007) 4580-4588
14. Roopenian D.C., Christianson G.J., Sproule T.J., et al. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J. Immunol. 170 (2003) 3528-3533
15. Junghans R.P., and Anderson C.L. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 5512-5516
16. Israel E.J., Patel V.K., Taylor S.F., Marshak-Rothstein A., and Simister N.E. Requirement for a beta 2-microglobulin-associated Fc receptor for acquisition of maternal IgG by fetal and neonatal mice. J. Immunol. 154 (1995) 6246-6251
17. Waldmann T.A., and Terry W.D. Familial hypercatabolic hypoproteinemia. A disorder of endogenous catabolism of albumin and immunoglobulin. J. Clin. Invest. 86 (1990) 2093-2098
18. Wani M.A., Haynes L.D., Kim J., et al. Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 5084-5089
19. Minchiotti L., Galliano M., Kragh-Hansen U., and Peters Jr. T. Mutations and polymorphisms of the gene of the major human blood protein, serum albumin. Hum. Mutat. 29 (2008) 1007-1016
20. http://www.albumin.org.
21. Petersen C.E., Ha C.E., Jameson D.M., and Bhagavan N.V. Mutations in a specific human serum albumin thyroxine binding site define the structural basis of familial dysalbuminemic hyperthyroxinemia. J. Biol. Chem. 271 (1996) 19110-19117
22. Chaudhury C., Brooks C.L., Carter D.C., Robinson J.M., and Anderson C.L. Albumin binding to FcRn: distinct from the FcRn-IgG interaction. Biochemistry 45 (2006) 4983-4990
23. Dolcini L., Caridi G., Dagnino M., et al. Analbuminemia produced by a novel splicing mutation. Clin. Chem. 53 (2007) 1549-1552
24. Andersen J.T., and Sandlie I. A receptor-mediated mechanism to support clinical observation of altered albumin variants. Clin. Chem. 53 (2007) 2216
25. Berntzen G., Lunde E., Flobakk M., Andersen J.T., Lauvrak V., and Sandlie I. Prolonged and increased expression of soluble Fc receptors, IgG and a TCR-Ig fusion protein by transiently transfected adherent 293E cells. J. Immunol. Methods 298 (2005) 93-104
26. Kaplan W., Husler P., Klump H., Erhardt J., Sluis-Cremer N., and Dirr H. Conformational stability of pGEX-expressed Schistosoma japonicum glutathione S-transferase: a detoxification enzyme and fusion-protein affinity tag. Protein Sci. 6 (1997) 399-406
27. Tudyka T., and Skerra A. Glutathione S-transferase can be used as a C-terminal, enzymatically active dimerization module for a recombinant protease inhibitor, and functionally secreted into the periplasm of Escherichia coli. Protein Sci. 6 (1997) 2180-2187
28. Ober R.J., Radu C.G., Ghetie V., and Ward E.S. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int. Immunol. 13 (2001) 1551-1559
29. Andersen J.T., Justesen S., Berntzen G., et al. A strategy for bacterial production of a soluble functional human neonatal Fc receptor. J. Immunol. Methods 331 (2008) 39-49
30. Andersen J.T., Justesen S., Fleckenstein B., et al. Ligand binding and antigenic properties of a human neonatal Fc receptor with mutation of two unpaired cysteine residues. FEBS J. 275 (2008) 4097-4110
31. Iwao Y., Anraku M., Yamasaki K., et al. Oxidation of Arg-410 promotes the elimination of human serum albumin. Biochim. Biophys. Acta 1764 (2006) 743-749
32. Iwao Y., Hiraike M., Kragh-Hansen U., et al. Altered chain-length and glycosylation modify the pharmacokinetics of human serum albumin. Biochim. Biophys. Acta 2009 (1794) 634-641
33. Iwao Y., Hiraike M., Kragh-Hansen U., et al. Changes of net charge and alpha-helical content affect the pharmacokinetic properties of human serum albumin. Biochim. Biophys. Acta 1774 (2007) 1582-1590
34. Sheffield W.P., Marques J.A., Bhakta V., and Smith I.J. Modulation of clearance of recombinant serum albumin by either glycosylation or truncation. Thromb. Res. 99 (2000) 613-621
35. Nimmerjahn F., and Ravetch J.V. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 8 (2008) 34-47
36. Kim J., Bronson C.L., Hayton W.L., et al. Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces. Am. J. Physiol. Gastrointest. Liver Physiol. 290 (2006) G352-G360
37. Kim J., Hayton W.L., Robinson J.M., and Anderson C.L. Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model. Clin. Immunol. 122 (2007) 146-155
38. Bertolotti-Ciarlet A., Wang W., Lownes R., et al. Impact of methionine oxidation on the binding of human IgG1 to FcRn and Fcgamma receptors. Mol. Immunol. 46 (2009) 1878-1882
39. Pan H., Chen K., Chu L., Kinderman F., Apostol I., and Huang G. Methionine oxidation in human IgG2 Fc decreases binding affinities to protein A and FcRn. Protein Sci. 18 (2009) 424-433
40. Sugio S., Kashima A., Mochizuki S., Noda M., and Kobayashi K. Crystal structure of human serum albumin at 2.5 A resolution. Protein Eng. 12 (1999) 439-446
41. Andersen J.T., and Sandlie I. The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics. Drug Metab. Pharmacokinet. 24 (2009) 318-332
42. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J. Control. Release 132 (2008) 171-183
43. Subramanian G.M., Fiscella M., Lamouse-Smith A., Zeuzem S., and McHutchison J.G. Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C. Nat. Biotechnol. 25 (2007) 1411-1419